U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07276425) titled 'Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis' on Nov. 28.
Brief Summary: With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
Study Start Date: June 01
Study Type: OBSERVATIONAL
Condition:
Prurigo Nodularis (PN)
Intervention:
DRUG: Dupilumab
In the Netherlands, the standard care for patients with moderate-to-severe prurigo nodularis who have failed or are contraindicated to conventional systemic immunosu...